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Abstract
Objective
To assess whether the x-ray attenuation of intra-arterial obstruction measured on non-con-
trast CT in ischemic stroke can predict response to thrombolysis and subsequent functional
outcome.
Methods
The Third International Stroke Trial (IST-3) was a multicenter randomized-controlled trial of
intravenous thrombolysis (rt-PA) given within six hours of ischemic stroke. Ethical approval
and informed consent were obtained. In a subgroup of 109 IST-3 patients (38 men, median
age 82 years), a single reader, masked to all clinical and other imaging data, manually mea-
sured x-ray attenuation (Hounsfield Units, HU) on non-contrast CT at the location of angio-
graphically-proven intra-arterial obstructions, pre-randomization and at 24–48 hour follow-
up. We calculated change in attenuation between scans. We assessed the impact of pre-
randomization arterial obstruction attenuation on six-month functional outcome.
Results
Most arterial obstructions (64/109, 59%) were hyperattenuating (mean 51.0 HU). Compared
with control, treatment with rt-PA was associated with a greater, but non-significant, reduc-
tion in obstruction attenuation at follow-up (-8.0 HU versus -1.4 HU in patients allocated con-
trol, p = 0.117). In multivariable ordinal regression analysis controlled for patient age, stroke
severity, location and extent of obstruction, time from stroke onset to baseline scan and rt-
PA treatment allocation, the attenuation of pre-randomization arterial obstruction was not
independently associated with six-month outcome (odds ratio = 0.99, 95% confidence inter-
val = 0.94–1.03, p = 0.516).
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Conclusions
In ischemic stroke, the x-ray attenuation of the arterial obstruction may decline more rapidly
from baseline to 24–48 hours following treatment with thrombolysis but we found no evi-
dence that baseline arterial obstruction attenuation predicts six-month outcome.
Introduction
Histological analysis of intra-arterial obstructions such as thrombus or embolus extracted from
ischemic stroke patients has suggested that obstructions with a greater red blood cell composi-
tion have a higher x-ray attenuation on CT (appear more white, are more dense) than obstruc-
tions which are predominantly fibrin based or of a mixed composition [1–3]. It has been
postulated that the response to thrombolytic therapy may therefore be different among stroke
patients with intra-arterial obstructions of differing x-ray attenuations. A few cohort studies
have suggested that measurement of intra-arterial x-ray attenuation at the location of an
obstruction on baseline non-contrast CT may help to predict recanalization following treat-
ment with intravenous thrombolysis in stroke [4–6]. There has, however, been very little
assessment of whether the improved rate of recanalization translates to an improvement in
functional outcome following stroke [7,8]. To our knowledge, the importance of x-ray attenua-
tion of arterial obstructions for predicting outcome has never been assessed in a randomized-
controlled trial testing intravenous thrombolysis.
The Third International Stroke Trial (IST-3) was a large multi-center, randomized-con-
trolled trial which tested intravenous thrombolysis (recombinant tissue plasminogen activator,
rt-PA) given within 6 hours of ischemic stroke [9]. Baseline and follow-up brain imaging was
performed for all IST-3 patients. In some centers, CT or MR angiography was also routinely
obtained pre-randomization [10].
In this post-hoc subgroup exploration of IST-3 trial data we wished to investigate, in
patients with ischemic stroke and an angiographically-proven intra-arterial obstruction at
baseline, whether the x-ray attenuation of the obstruction is predictive of six-month functional
outcome. We also aimed to measure short-term changes in the attenuation of arterial obstruc-
tion following treatment with intravenous rt-PA.
Materials and Methods
The Third International Stroke Trial
IST-3 was an international, multi-center, prospective, randomized, open, blinded endpoint
(PROBE) trial of intravenous rt-PA in ischemic stroke. Ethical approval for IST-3 was granted
by the Multicentre Research Ethics Committees, Scotland (MREC/99/0/78) and by local ethics
committees. Research was undertaken in accordance with the Declaration of Helsinki. Patient
enrolment, data collection, image analysis and adherence to CONSORT recommendations
have been previously described [9,11]. Briefly, patients with acute stroke of any severity, with
no upper age limit, were eligible for inclusion in the trial if intravenous rt-PA (alteplase) could
be started within 6 hours of stroke onset and CT/MR imaging had excluded both intracranial
hemorrhage and any structural stroke mimic. Written informed consent was obtained for all
patients. Stroke severity prior to randomization was assessed with the National Institutes of
Health Stroke Scale (NIHSS). Clinical stroke syndrome at baseline was assessed with the
Oxfordshire Community Stroke Project (OCSP) classification [12]. After entry of baseline
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data, patients were randomized to receive intravenous rt-PA (0.9mg/Kg) or control. Patients
were followed by postal questionnaire or telephone interview at six-months and functional sta-
tus assessed with the Oxford Handicap Scale (OHS). IST-3 is registered with the Current Con-
trolled Trials database, ISRCTN25765518, http://www.controlled-trials.com/
ISRCTN25765518.
The imaging protocol required that non-contrast CT scans extend from the foramen mag-
num to vertex, with maximum slice thickness 4–5 mm through the posterior fossa and 8–10
mm for the cerebral hemispheres. There was no pre-defined requirement for thin-slice sections
and all acquired data including spiral volumes were accepted. CT or MR angiography (CTA
and MRA, respectively) were also collected if available; the published protocol for the IST-3
angiography substudy specified minimum acquisition standards [10]. Only IST-3 patients who
had CTA or MRA performed within 2 hours of baseline non-contrast CT are included in this
present analysis. We recorded time from stroke onset to baseline scan. Follow-up non-contrast
CT imaging was also performed for all patients at 24–48 hours; follow-up delay was also
recorded. Follow-up angiography was not mandatory in the IST-3 angiography substudy [10].
Image analysis
A single neuroradiologist independently evaluated all baseline angiography in IST-3, blind to
treatment allocation, clinical details and outcome, to identify patients for subgroup analysis,
i.e. those with a filling defect on angiography that could be assessed on the corresponding non-
contrast CT. Previous IST-3 scan reading panel assessments were not used for this report.
Image analysis was also performed blind to any subsequent imaging or other scan reads. Image
evaluation was performed using standard DICOM software (Digital Jacket, DesAcc, Bellevue,
WA, USA). Results were entered into a database using a pre-validated structured proforma
(available at: http://www.bric.ed.ac.uk/research/imageanalysis.html).
Angiography was assessed using the IST-3 angiography score [10]: 0 = occluded, 1 =minimal
patency (some contrast penetrates obstruction but none or only a minimal amount enters distal
artery), 2 = patency<50% of the lumen at the point of obstruction and a) only partly filling
(<half) or b) incomplete filling (but>half) of the major branches of the affected artery,
3 = patency>50% of the lumen and filling of most of the branches of the affected artery,
4 = normal. We have previously demonstrated inter- and intra-observer reliability for the IST-
3 angiography score in the assessment of CTA; inter-observer agreement was substantial for
both (Krippendorff’s Alpha = 0.66 and 0.63, respectively) [13]. We stratified angiographic
obstruction by the three largest intracranial arterial segments involved: internal carotid artery
(ICA), main stem of middle cerebral artery (MCA), sylvian branch of MCA, anterior cerebral
artery (ACA), posterior cerebral artery (PCA), vertebral artery (VA) and the basilar artery
(BA). To assess the extent of ischemia on baseline non-contrast CT we calculated ASPECTS
(Alberta Stroke Program Early CT Score) for all patients [14].
Intra-arterial x-ray attenuation was measured on the non-contrast CT with reference to the
concurrent abnormal CTA/MRA. Simultaneous parallel viewing of the non-contrast CT and
the CTA/MRA allowed for attenuation measures (Hounsfield Units, HU) to be taken from
within the same location on non-contrast CT that corresponded with the filling defect on angi-
ography (i.e. the obstruction). Patients were excluded from the study if the obstruction was
insufficient to allow for attenuation measures to be performed (i.e. minor stenosis without a
discrete measurable filling defect). In addition to analysing the obstruction, we also obtained
attenuation measures within the equivalent contralateral normal artery if possible (for example,
the opposite MCA at an equivalent location) and also within the basilar artery. We therefore
measured intra-arterial attenuation at three intra-cranial locations for most patients (one
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obstructed artery and two normal controls). At each location, three separate elliptical regions
of interest were applied by hand, to include as much of the intra-vascular area as possible but
taking care not to include the arterial wall or any surrounding tissue; a mean attenuation value
of the three readings was later calculated. Attenuation measurements were performed follow-
ing x2 magnification of images (Fig 1). The subjective appearance of arterial obstruction on
baseline non-contrast CT was also noted as either isoattenuating to normal vessels or hyperat-
tenuating (if obstruction appeared brighter than adjacent or equivalent contralateral arteries
but non-calcified [15]). We measured the length of hyperattenuated arterial obstructions on
non-contrast CT. We calculated HU ratios for each patient to assess attenuation of the obstruc-
tion in relation to normal background intra-arterial attenuation as: mean obstruction HU
mean normal vessel HU. We repeated obstruction attenuation measurements, in the same loca-
tion, on follow-up non-contrast CT. We calculated change in attenuation of the obstruction
between the two scans.
Statistical analysis
We used t-tests and Mann-Whitney U-tests to compare characteristics of the subgroup and the
full IST-3 population and to compare attenuation values, as appropriate. We used Pearson’s
correlation coefficient, analysis of variance and t-tests to look for associations between baseline
obstruction HU and clinical characteristics, other imaging appearances and outcome in sepa-
rate univariate analyses. Similarly and as previously described [9,16,17], we used adjusted mul-
tivariable ordinal regression analysis (adjusted for patient age, time from stroke onset to
baseline scan, NIHSS, location of arterial obstruction, extent of arterial obstruction, IST-3 angi-
ography score and treatment allocation) to look for independent associations between baseline
attenuation of obstruction and outcome. Two adjusted regression analyses were performed: the
first included attenuation of obstruction as a continuous variable (i.e. absolute HU, quantita-
tive); the second included attenuation as a dichotomous variable (i.e. iso- or hyper-attenuating,
qualitative).
All analyses were performed using IBM SPSS Statistics software, version 20.0 (IBM Corpo-
ration, Armonk, NY, USA). We considered a p-value<0.05 significant.
Results
IST-3 subgroup
In IST-3, 109 patients with baseline angiography (108 CTA and 1 MRA) had both a concurrent
non-contrast CT and a measurable angiographic stenosis or occlusion. Compared with the
whole IST-3 trial population (n = 3035), this subgroup had significantly more severe strokes at
baseline (median NIHSS 17 versus 11 for the whole trial, p<0.001), a different distribution of
clinical stroke syndromes (e.g. more total anterior circulation infarcts, 62.4% versus 42.3% for
the whole trial, and fewer lacunar infarcts, 3.7% versus 11.2% for the whole trial, p<0.001),
more extensive ischemia visible on baseline non-contrast CT (median ASPECTS 9 versus 10
for the whole trial, p = 0.001) and a worse six-month functional outcome (median OHS 5 ver-
sus 4 for the whole trial, p<0.001). In addition, there were significantly fewer men in the sub-
group (35% versus 48% in the whole trial, p = 0.004). There were no significant differences in
patient age (median 82 years in subgroup), presence of baseline atrial fibrillation (n = 35,
32.1% of subgroup), percentage treated with rt-PA (n = 51, 46.8% of subgroup), time from
stroke onset to baseline scan (mean 171 minutes in subgroup), time to randomization (mean
230 minutes in subgroup) or time to imaging follow-up (median 25 hours in subgroup)
between the subgroup and the whole IST-3 trial, S1 Table.
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Imaging findings
Table 1 demonstrates the results of imaging assessment for the 109 patients. We identified a
hyperattenuating artery in 64 patients (59%). Within these hyperattenuating arterial obstruc-
tions, the mean was 51.0 HU. This compares with a mean of 37.9 HU in isoattenuating
obstructions, p<0.001. The mean within normal vessels (i.e. normally flowing blood) was 38.1
HU. The mean HU ratio of hyperattenuating obstructions was 1.38 compared with a mean HU
ratio of 0.97 for isoattenuating obstructions, p<0.001. The majority of patients had obstruc-
tions within the ICA (20%) or MCA (75%). In most patients, obstruction was isolated to a sin-
gle arterial segment (56%), fewer patients had obstruction affecting 2 or 3 arterial segments
(37% and 7%, respectively). The mean length of hyperattenuating arterial segment on non-con-
trast CT was 19 mm (standard deviation 10 mm). By IST-3 angiography score, most patients
had>50% luminal stenosis (84%) and in 44%, there was either complete occlusion or severe
luminal stenosis.
Associations with obstruction attenuation at baseline
On univariate analysis, there was no significant difference in the mean attenuation of baseline
arterial obstruction when patients with versus without atrial fibrillation were compared (45.9
HU versus 45.5 HU, respectively, p = 0.859) or among the different clinical stroke subtypes
(F = 1.5, p = 0.220). Similar non-significant results were obtained in all cases if those with
hyper- versus iso-attenuating arterial obstructions were compared. There was no correlation
between the length of the hyperattenuating arterial segment and the attenuation of that
obstruction (r = 0.03, p = 0.825). Similarly, the mean attenuation of arterial obstruction at base-
line did not differ between those with 1 versus those with 2 or 3 obstructed arterial segments
(44.8 HU versus 46.6 HU, respectively, p = 0.418). Finally, there was no correlation between
Fig 1. Intra-arterial HUmeasurement technique. For each intra-arterial measurement location (level of
obstruction, contralateral normal vessel, basilar artery), 3 elliptical regions of interest were applied by hand on
a magnified image. Note that Ellipse 1 is placed within the horizontal segment of the right middle cerebral
artery. HU = Hounsfield Unit.
doi:10.1371/journal.pone.0145683.g001
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the time from stroke onset to baseline scan and the attenuation of arterial obstruction on the
baseline scan (r = 0.13, p = 0.203).
Effect of rt-PA on obstruction attenuation
The median time between baseline and follow-up non-contrast CT scans was 25 hours. At fol-
low-up, hyperattenuating obstructions had reduced to a mean of 45.1 HU while isoattenuating
obstructions were unchanged at mean 38.2 HU. There was a non-significantly (p = 0.117)
greater reduction of attenuation between baseline and follow-up non-contrast CT for arterial
Table 1. Imaging characteristics of the IST-3 subgroup with measurable intra-arterial obstruction
(n = 109).
A
Intra-arterial X-ray attenuation on non-contrast CT Mean (SD)
HU of hyperattenuating obstruction at baseline (mean, SD) 51.0 (8.3)
HU of isoattenuating obstruction at baseline (mean, SD) 37.9 (10.7)
HU of non-obstructed vessel (mean, SD) 38.1 (5.2)
HU at follow-up of obstructions hyperattenuating at baseline (mean, SD) 45.1 (9.2)
HU at follow-up of obstructions isoattenuating at baseline (mean, SD) 38.2 (8.2)
Ratio of obstruction: normal vessel for obstructions hyperattenuating at baseline (mean, SD) 1.38 (0.23)
Ratio of obstruction: normal vessel HU for obstructions isoattenuating at baseline (mean, SD) 0.97 (0.21)
B
Angiographic location of arterial obstruction n (%)
ICA 22 (20.2)
MCA mainstem 61 (55.9)
MCA sylvian branch 21 (19.3)
ACA 0
PCA 0
Vertebral artery 2 (1.8)
Basilar artery 3 (2.8)
C
Number of obstructed arterial segments on angiography n (%)
1 61 (56.0)
2 40 (36.7)
3 8 (7.3)
D
IST-3 Angiography Scorea n (%)
0 11 (10.1)
1 37 (33.9)
2a 17 (15.6)
2b 27 (24.8)
3 17 (15.6)
4 0
HU = Hounsﬁeld Units. SD = Standard Deviation. ICA = Internal Carotid Artery. MCA = Middle Cerebral
Artery. ACA = Anterior Cerebral Artery. PCA = Posterior Cerebral Artery.
aIST-3 angiography scoring: 0 = occluded, 1 = minimal patency (some contrast penetrates obstruction but
no/minimal enters distal artery), 2 = patency <50% of the lumen at the point of obstruction and a) only
partly ﬁlling (<half) or b) incomplete ﬁlling (but >half) of the major branches of the affected artery,
3 = patency >50% of the lumen and ﬁlling of most of the branches of the affected artery, 4 = normal artery.
doi:10.1371/journal.pone.0145683.t001
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obstructions in patients treated with rt-PA (median reduction of 8.0 HU) versus controls
(median reduction of 1.4 HU), Fig 2. Similar results were obtained if only patients with hyper-
attenuating obstructions at baseline were included; median reduction of 8.4 HU in those
treated with rt-PA versus a median reduction of 0.5 HU in those allocated control, p = 0.094.
Analysis includes patients with both iso- and hyper-attenuating obstructions at baseline.
There was no significant difference between the groups treated with thrombolysis (median
-8.0 HU, IQR -12.4 to 2.5) and control (median -1.4 HU, IQR -8.7 to 2.9), p = 0.117.
Obstruction attenuation and six-month outcome
There were no significant associations on univariate analysis between the attenuation of arterial
obstruction at baseline and six-month functional outcome in either the rt-PA or control
groups. For correlation between baseline obstruction attenuation and six-month OHS the
results were: r = 0.03, p = 0.851 for those treated with rt-PA (n = 51) and r = 0.13, p = 0.342 in
the control group (n = 58). Comparing baseline arterial obstruction attenuation between the
patients reaching independence (OHS 0–2) and those patients dependent or dead at six months
(OHS 3–6), the mean attenuation difference was: 0.2 HU, p = 0.944 for those treated with rt-
PA and 1.5 HU, p = 0.673 in the control group. In both cases, baseline HU values were non-sig-
nificantly higher among patients with poor six-month functional outcome (OHS 3–6).
In the main IST-3 trial (n = 3035), in an adjusted ordinal regression analysis, rt-PA treat-
ment was associated with a favourable shift in OHS (better outcomes) at six months (common
odds ratio, OR = 1.27, 95%CI = 1.10–1.47; p = 0.001) [9]. Among subgroup patients (n = 109),
our estimates of rt-PA effect on OHS derived using similar adjusted ordinal regression analyses
were not materially different (e.g. OR = 2.17, 95%CI = 0.80–5.91) to the main IST-3 trial results
but were less precise because of the small sample size. We additionally found no evidence that
baseline arterial obstruction attenuation was an independent predictor of outcome in either the
quantitative (absolute HU of obstruction, OR = 0.99, 95%CI = 0.94–1.03, p = 0.516) or qualita-
tive analyses (hyper- versus iso-attenuating obstruction, OR = 0.53, 95%CI = 0.20–1.41,
p = 0.203), Tables 2 and 3 respectively. There was a non-significant trend towards poorer out-
come among patients with hyperattenuating rather than isoattenuating obstructions.
For all analyses, replacing absolute arterial obstruction attenuation values with obstruction
attenuation ratios did not alter the results (data not shown).
Discussion
These data from an angiographic substudy within the largest randomized controlled-trial test-
ing intravenous rt-PA in ischemic stroke do not support the hypothesis that baseline x-ray
attenuation of intra-arterial obstruction measured on non-contrast CT is an independent pre-
dictor of functional outcome at 6 months. Since age, baseline stroke severity and time to treat-
ment are such powerful predictors of outcome after ischemic stroke treated with intravenous
thrombolysis, it is perhaps not surprising that we have been unable to show that measuring the
attenuation of arterial obstruction adds predictive value for decisions about intravenous rt-PA
treatment.
The value of measuring arterial obstruction attenuation on CT to select patients for treat-
ment is conflicting. Two non-randomized studies (both around 100 patients) found no associa-
tion between the attenuation of arterial obstruction and outcome after thrombolysis [7,8].
Three smaller cohort studies have however demonstrated with highly consistent results that
intravenous thrombolysis more often resulted in successful arterial recanalization in patients
with highly attenuating obstructions at baseline. Puig et. al. (n = 45) demonstrated a mean rela-
tive HU (equivalent to mean HU ratio in our study) of 1.57 for patients achieving
Attenuation of Arterial Obstruction in Stroke
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recanalization versus 1.11 for those without recanalization (p<0.001) [4]. Similarly, Moftakhar
et. al. (n = 90) demonstrated a mean relative HU of 1.58 in patients that recanalized versus 1.39
in those that did not (p = 0.01) [5]. Finally, Niesten et. al. (n = 88) demonstrated a mean rela-
tive HU of 1.54 in patients that recanalized versus 1.29 in those that did not (p<0.001) [6]. We
unable to assess recanalization following treatment with intravenous rt-PA as follow-up angi-
ography was not mandatory in IST-3. The apparent discrepancy between our results and these
three cohort studies may indicate that success of recanalization therapy is not the only predic-
tor of outcome. Indeed the literature assessing relationships between the attenuation of
obstruction and success of endovascular thrombus retrieval, has demonstrated that while
recanalization is more likely with hyperattenuating obstructions, where reported, this does not
translate to a proportionally improved functional outcome [18–22]. In addition, some authors
have identified significant differences in arterial obstruction attenuation when stroke cohorts
are stratified by etiological stroke subtype. For example, cardioembolic thrombus may be more
attenuating than atherothrombotic thrombus [4,23], but such results have not always been rep-
licated [8] and a large retrospective analysis of over 8000 patients failed to demonstrate an
Fig 2. Effect of thrombolysis on change in attenuation of arterial obstruction between baseline and
follow-up CT. A negative change in arterial obstruction HU (Hounsfield Units) between baseline and follow-
up CT indicates a reduction in attenuation of the obstruction.
doi:10.1371/journal.pone.0145683.g002
Table 2. Ordinal regression analysis with six-month OHS as the dependant variable (n = 109); attenuation of obstruction is included as a quantita-
tive continuous variable.
Odds Ratioa 95% Conﬁdence Interval p-value
Age (years) 0.95 0.92–0.98 0.001
Time from stroke onset to baseline scan (hours) 1.12 0.78–1.62 0.539
NIHSS 0.85 0.79–0.92 <0.0001
Baseline attenuation (HU) of arterial obstruction 0.99 0.94–1.03 0.516
Location of arterial obstruction 1.10 0.73–1.68 0.645
Number of obstructed arterial segments (1–3) 0.70 0.30–1.62 0.407
IST-3 angiography score (0–3) 1.03 0.71–1.51 0.865
Treated with rt-PA (versus control) 2.17 0.80–5.91 0.131
NIHSS = National Institutes of Health Stroke Scale. HU = Hounsﬁeld Units. rt-PA = recombinant tissue plasminogen activator.
aOdds ratio <1 indicates a worse outcome.
doi:10.1371/journal.pone.0145683.t002
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independent association between hyperattenuating thrombus and stroke etiology [24]. We
similarly did not find any association in IST-3 between clinical stroke subtype (which may vary
with differing underlying etiologies [12]) or the presence of atrial fibrillation and the attenua-
tion of arterial obstruction.
Our secondary analysis assessing the change in attenuation of arterial obstruction from
baseline to short-term follow-up CT is consistent with the hypothesis that the HU of obstruc-
tion may reduce more rapidly in patients given intravenous rt-PA than controls; however, the
observed difference in attenuation was non-significant. This result is also consistent with IST-3
data showing that intravenous thrombolysis accelerates the removal of the hyperattenuating
artery sign (evident at baseline in over 700 patients), a recognised surrogate for intra-arterial
thrombus [17].
Our study has limitations. In a large pragmatic multicenter trial like IST-3 there is inevitably
some variability in scan parameters and protocols but, nevertheless, the study design closely
represents normal working practice. We cannot however exclude the possibility that x-ray
attenuation of arterial obstructions was under-estimated due to partial volume effects of thick
CT slices for some patients. Similarly, partial volume effects may have reduced the accuracy of
attenuation measurements in some cases. IST-3 angiography was performed only in some cen-
ters and may therefore be biased toward patients for whom it could convey the greatest per-
ceived benefit. Though our total patient numbers for this assessment are similar to previous
work, our analyses are underpowered. But as a randomized-controlled trial, IST-3 provides an
unbiased assessment of the relationships between the use of intravenous rt-PA and functional
outcome and our estimate of the rt-PA effect on outcome in this subgroup is not substantially
different from that reported in the full IST-3 trial. A single reader manually applied regions of
interest to measure intra-arterial attenuation in our study. Repeat assessment by a secondary
reader or use of an automated segmentation program may have improved the accuracy of the
data collected. We used standardized and pre-validated methods of accessing and scoring
imaging with blinding of the reader to allow for robust and repeatable data collection.
Conclusions
These data from a prospective analysis of a randomized-controlled trial do not provide evi-
dence that measurement of the x-ray attenuation of arterial obstruction on CT adds useful
additional information on prognosis or response to intravenous thrombolysis in patients with
ischemic stroke.
Table 3. Ordinal regression analysis with six-month OHS as the dependant variable (n = 109); attenuation of obstruction is included as a qualita-
tive dichotomous variable.
Odds Ratioa 95% Conﬁdence Interval p-value
Age (years) 0.95 0.92–0.98 0.001
Time from stroke onset to baseline scan (hours) 1.13 0.79–1.63 0.508
NIHSS 0.86 0.79–0.92 <0.0001
Hyperattenuating obstruction at baseline (versus isoattenuating obstruction) 0.53 0.20–1.41 0.203
Location of arterial obstruction 1.12 0.75–1.67 0.589
Number of obstructed arterial segments (1–3) 0.70 0.30–1.60 0.396
IST-3 angiography score (0–3) 1.02 0.70–1.49 0.902
Treated with rt-PA (versus control) 2.29 0.85–6.17 0.102
NIHSS = National Institutes of Health Stroke Scale. rt-PA = recombinant tissue plasminogen activator.
aOdds ratio <1 indicates a worse outcome.
doi:10.1371/journal.pone.0145683.t003
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Supporting Information
S1 Table. Clinical characteristics of the full IST-3 trial population and the subgroup with
measurable intra-arterial obstruction on angiography.
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